Angiotensin IV suppresses inflammation in the brains of rats with chronic cerebral hypoperfusion. (September 2018)

• Record Type: Journal Article
• Authors: Wang, Qing-Guang; Xue, Xiao; Yang, Yang; Gong, Peng-Yu; Jiang, Teng; Zhang, Ying-Dong
• Is Part Of: Journal of the renin-angiotensin-aldosterone system. Volume 19:Number 3(2018)
• Publication Date: 2018-09
• Subjects: Angiotensin IV -- chronic cerebral hypoperfusion -- inflammation -- vascular dementia -- Alzheimer's disease; Renin-angiotensin system -- Periodicals; 616.132
• DOI: 10.1177/1470320318799587
• Languages: English
• ISSNs: 1470-3203

Abstract

Introduction: This study aimed to evaluate the influence of central angiotensin IV (Ang IV) infusion on chronic cerebral hypoperfusion (CCH)-related neuropathological changes including amyloid-β (Aβ), hyperphosphorylated tau (p-tau) and the inflammatory response. Materials and methods: Rats with CCH received central infusion of Ang IV, its receptor AT4 R antagonist divalinal-Ang IV or artificial cerebrospinal fluid for six weeks. During this procedure, the systolic blood pressure (SBP) was monitored, and the levels of Aβ42, p-tau and pro-inflammatory cytokines in the brain were detected. Results: Rats with CCH exhibited higher levels of Aβ42, p-tau and pro-inflammatory cytokines in the brain when compared with controls. Infusion of Ang IV significantly reduced the expression of pro-inflammatory cytokines in the brains of rats with CCH. Meanwhile, the reduction of pro-inflammatory cytokines levels caused by Ang IV was reversed by divalinal-Ang IV. During the treatment, the SBP in rats was not significantly altered. Conclusion: This study demonstrates for the first time that Ang IV dose-dependently suppresses inflammation through AT4 R in the brains of rats with CCH, which is independent from SBP. These findings suggest that Ang IV/AT4 R may represent a potential therapeutic target for CCH-related neurological diseases.